FDA Implements Naming Regulations for Biosimilars

The Center for Biosimilars reported late last week that the Food and Drug Administration has started implementing its long-delayed naming regulations for biosimilars. The hotly debated process will add a 4-letter suffix, devoid of meaning, to the end of newly approved biologics’ non-proprietary names. The move reflects a change in previous policy that only added the suffixes to biosimilars’ non-proprietary names.

Become a Member

Whether you have an established practice, you’re fresh out of your fellowship, or you’re a hospital-based rheumatologist considering private practice, United Rheumatology offers the resources and services you need to advance your career and your clinic.


Find a UR Rheumatologist Near Me

© 2023 United Rheumatology